NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for NeuroPace in a research note issued on Wednesday, March 5th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.54) per share for the year, up from their prior forecast of ($0.80). Cantor Fitzgerald has a "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.
Several other analysts have also recently commented on the company. Wells Fargo & Company increased their target price on NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their target price on NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a report on Tuesday, December 17th. Finally, UBS Group initiated coverage on NeuroPace in a report on Tuesday, January 21st. They set a "buy" rating and a $17.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.20.
Check Out Our Latest Analysis on NPCE
NeuroPace Price Performance
NASDAQ:NPCE traded down $0.18 during trading hours on Friday, reaching $11.00. The company had a trading volume of 271,316 shares, compared to its average volume of 120,525. The stock has a 50-day moving average of $12.73 and a two-hundred day moving average of $9.82. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The firm has a market capitalization of $328.33 million, a PE ratio of -11.00 and a beta of 2.06. NeuroPace has a one year low of $5.45 and a one year high of $15.77.
NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The firm had revenue of $21.47 million for the quarter, compared to analysts' expectations of $21.14 million.
Insider Activity
In other news, insider Martha Morrell sold 3,200 shares of the company's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now owns 87,062 shares of the company's stock, valued at $1,306,800.62. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total value of $49,545,943.00. The disclosure for this sale can be found here. Insiders have sold 5,352,479 shares of company stock valued at $50,670,217 over the last 90 days. 22.20% of the stock is owned by company insiders.
Hedge Funds Weigh In On NeuroPace
Several large investors have recently made changes to their positions in NPCE. KCK LTD. acquired a new position in NeuroPace in the fourth quarter valued at about $58,981,000. Barclays PLC lifted its stake in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company's stock valued at $144,000 after buying an additional 16,007 shares during the period. State Street Corp lifted its stake in NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company's stock valued at $1,084,000 after buying an additional 12,912 shares during the period. Geode Capital Management LLC lifted its stake in NeuroPace by 8.7% in the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock valued at $2,211,000 after buying an additional 25,330 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock valued at $84,000 after buying an additional 6,181 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
